| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
|
André, F.
|
|
|
32 |
2 |
p. 208-217
|
article
|
| 2 |
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
|
Nicolle, R.
|
|
|
32 |
2 |
p. 250-260
|
article
|
| 3 |
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
|
Magbanua, M.J.M.
|
|
|
32 |
2 |
p. 229-239
|
article
|
| 4 |
Editorial Board
|
|
|
|
32 |
2 |
p. iii
|
article
|
| 5 |
Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review
|
Deftereos, S.N.
|
|
|
32 |
2 |
p. 282-283
|
article
|
| 6 |
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
|
Xu, B.
|
|
|
32 |
2 |
p. 218-228
|
article
|
| 7 |
Erratum to “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Cardoso, F.
|
|
|
32 |
2 |
p. 284
|
article
|
| 8 |
How often do highly promising cancer biology discoveries translate into effective treatments?
|
Waters, R.S.
|
|
|
32 |
2 |
p. 136-138
|
article
|
| 9 |
Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?
|
Khaddour, K.
|
|
|
32 |
2 |
p. 279-280
|
article
|
| 10 |
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
|
Fenaux, P.
|
|
|
32 |
2 |
p. 142-156
|
article
|
| 11 |
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up †
|
Roth, P.
|
|
|
32 |
2 |
p. 171-182
|
article
|
| 12 |
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer ☆
|
Eikesdal, H.P.
|
|
|
32 |
2 |
p. 240-249
|
article
|
| 13 |
Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report
|
Lau, B.
|
|
|
32 |
2 |
p. 280-282
|
article
|
| 14 |
Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting
|
Real, F.X.
|
|
|
32 |
2 |
p. 133-135
|
article
|
| 15 |
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial ☆
|
Dent, S.
|
|
|
32 |
2 |
p. 197-207
|
article
|
| 16 |
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
|
Lacouture, M.E.
|
|
|
32 |
2 |
p. 157-170
|
article
|
| 17 |
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
|
Casolino, R.
|
|
|
32 |
2 |
p. 183-196
|
article
|
| 18 |
SOLAR1s: alpelisib returns to earth?
|
Matikas, A.
|
|
|
32 |
2 |
p. 129-132
|
article
|
| 19 |
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
|
Subbiah, V.
|
|
|
32 |
2 |
p. 261-268
|
article
|
| 20 |
Table of Contents
|
|
|
|
32 |
2 |
p. i-ii
|
article
|
| 21 |
The complex balance of PI3K inhibition
|
Vanacker, H.
|
|
|
32 |
2 |
p. 127-128
|
article
|
| 22 |
The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: a valuable tool for clinicians
|
Sepúlveda-Sánchez, J.M.
|
|
|
32 |
2 |
p. 139-141
|
article
|
| 23 |
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
|
Saturno, G.
|
|
|
32 |
2 |
p. 269-278
|
article
|
Journal description